
NASDAQConsumer DefensiveHousehold & Personal Products
最新数据
US$6.90
−US$0.1021 · -1.46%
United-Guardian, Inc., operating both domestically and globally, specializes in the development, production, and distribution of a diverse range of cosmetic raw materials, pharmaceutical solutions, medical-grade lubricants, and proprietary industrial chemicals. Its extensive cosmetic ingredients catalog includes the LUBRAJEL line of water-based moisturizing and lubricating gel formulations, featuring variants such as LUBRAJEL NATURAL (derived from natural sources), LUBRAJEL MARINE, and LUBRASIL II SB (a silicone-infused LUBRAJEL formulation). Other key offerings in this category are LUBRAJEL II XD; B-122, a powdered lubricant suitable for pressed powders, eyeliners, blushes, and industrial uses; KLENSOFT, a surfactant for shampoos, shower gels, and makeup removers; and ORCHID COMPLEX, an oil-soluble base for skin creams, lotions, and cleansers. For medical applications, United-Guardian provides lubricants like LUBRAJEL RR and RC, which are water-based gels specifically designed for urinary catheters. LUBRAJEL MG serves to lubricate urinary catheters, pre-lubricated enema tips, and other medical devices. The company also offers LUBRAJEL LC and LUBRAJEL FA, specialized LUBRAJEL formulations tailored for oral care, alongside LUBRAJEL FLUID for lubricating various water-soluble products. The pharmaceutical portfolio features RENACIDIN, a prescription medication for preventing and dissolving calcifications in urethral catheters and the urinary bladder. Also included is CLORPACTIN WCS-90, an antimicrobial agent effective against infections in the urinary bladder, localized peritoneal infections, and infections affecting the eyes, ears, nose, throat, and sinuses. Industrial products comprise DESELEX, a sequestering and chelating agent vital for detergent manufacturing, and THOROCLENS, a powerful chlorine-based industrial cleaning solution. The firm also dedicates resources to research and development, primarily focusing on advancing cosmetic ingredients. Products are brought to market through a robust network of marketing partners, distributors, and wholesalers. Established in 1942, United-Guardian maintains its headquarters in Hauppauge, New York.
前收盘价
US$6.90
−US$0.1021 · -1.46%
盘后
US$6.90
US$0.00 · 0.00%
10月12日 16:04 ET
盘中时间采用ET。市场数据可能有所延迟。
United-Guardian, Inc., operating both domestically and globally, specializes in the development, production, and distribution of a diverse range of cosmetic raw materials, pharmaceutical solutions, medical-grade lubricants, and proprietary industrial chemicals. Its extensive cosmetic ingredients catalog includes the LUBRAJEL line of water-based moisturizing and lubricating gel formulations, featuring variants such as LUBRAJEL NATURAL (derived from natural sources), LUBRAJEL MARINE, and LUBRASIL II SB (a silicone-infused LUBRAJEL formulation). Other key offerings in this category are LUBRAJEL II XD; B-122, a powdered lubricant suitable for pressed powders, eyeliners, blushes, and industrial uses; KLENSOFT, a surfactant for shampoos, shower gels, and makeup removers; and ORCHID COMPLEX, an oil-soluble base for skin creams, lotions, and cleansers. For medical applications, United-Guardian provides lubricants like LUBRAJEL RR and RC, which are water-based gels specifically designed for urinary catheters. LUBRAJEL MG serves to lubricate urinary catheters, pre-lubricated enema tips, and other medical devices. The company also offers LUBRAJEL LC and LUBRAJEL FA, specialized LUBRAJEL formulations tailored for oral care, alongside LUBRAJEL FLUID for lubricating various water-soluble products. The pharmaceutical portfolio features RENACIDIN, a prescription medication for preventing and dissolving calcifications in urethral catheters and the urinary bladder. Also included is CLORPACTIN WCS-90, an antimicrobial agent effective against infections in the urinary bladder, localized peritoneal infections, and infections affecting the eyes, ears, nose, throat, and sinuses. Industrial products comprise DESELEX, a sequestering and chelating agent vital for detergent manufacturing, and THOROCLENS, a powerful chlorine-based industrial cleaning solution. The firm also dedicates resources to research and development, primarily focusing on advancing cosmetic ingredients. Products are brought to market through a robust network of marketing partners, distributors, and wholesalers. Established in 1942, United-Guardian maintains its headquarters in Hauppauge, New York.
日内区间
当前US$6.90
52周区间
当前US$6.90
盘中时间采用ET。市场数据可能有所延迟。
United-Guardian, Inc., operating both domestically and globally, specializes in the development, production, and distribution of a diverse range of cosmetic raw materials, pharmaceutical solutions, medical-grade lubricants, and proprietary industrial chemicals. Its extensive cosmetic ingredients catalog includes the LUBRAJEL line of water-based moisturizing and lubricating gel formulations, featuring variants such as LUBRAJEL NATURAL (derived from natural sources), LUBRAJEL MARINE, and LUBRASIL II SB (a silicone-infused LUBRAJEL formulation). Other key offerings in this category are LUBRAJEL II XD; B-122, a powdered lubricant suitable for pressed powders, eyeliners, blushes, and industrial uses; KLENSOFT, a surfactant for shampoos, shower gels, and makeup removers; and ORCHID COMPLEX, an oil-soluble base for skin creams, lotions, and cleansers. For medical applications, United-Guardian provides lubricants like LUBRAJEL RR and RC, which are water-based gels specifically designed for urinary catheters. LUBRAJEL MG serves to lubricate urinary catheters, pre-lubricated enema tips, and other medical devices. The company also offers LUBRAJEL LC and LUBRAJEL FA, specialized LUBRAJEL formulations tailored for oral care, alongside LUBRAJEL FLUID for lubricating various water-soluble products. The pharmaceutical portfolio features RENACIDIN, a prescription medication for preventing and dissolving calcifications in urethral catheters and the urinary bladder. Also included is CLORPACTIN WCS-90, an antimicrobial agent effective against infections in the urinary bladder, localized peritoneal infections, and infections affecting the eyes, ears, nose, throat, and sinuses. Industrial products comprise DESELEX, a sequestering and chelating agent vital for detergent manufacturing, and THOROCLENS, a powerful chlorine-based industrial cleaning solution. The firm also dedicates resources to research and development, primarily focusing on advancing cosmetic ingredients. Products are brought to market through a robust network of marketing partners, distributors, and wholesalers. Established in 1942, United-Guardian maintains its headquarters in Hauppauge, New York.
日内区间
当前US$6.90
52周区间
当前US$6.90
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目(USD) | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 1054.55万 USD | 1218.2万 USD | 1088.52万 USD | 1269.85万 USD | 1392.96万 USD |
| 销货成本 | 551.25万 USD | 572.16万 USD | 547.96万 USD | 599.64万 USD | 574.79万 USD |
| 毛利 | 503.29万 USD | 646.04万 USD | 540.56万 USD | 670.21万 USD | 818.17万 USD |
| 研究与开发 | 46.36万 USD | 45.68万 USD | 46.4万 USD | 49.08万 USD | 47.86万 USD |
| 营业费用 | 278.96万 USD | 281.36万 USD | 254.26万 USD | 266.49万 USD | 251.46万 USD |
| 利息收入 | 36.53万 USD | 43.47万 USD | 30.67万 USD | 23.67万 USD | 23.39万 USD |
| 利息支出 | — | — | — | 161.91万 USD | — |
| 折旧和摊销 | 10.82万 USD | 9.59万 USD | 10.57万 USD | 13.54万 USD | 14.6万 USD |
| 营业利润 | 224.33万 USD | 364.68万 USD | 286.3万 USD | 403.72万 USD | 566.71万 USD |
| 净利润 | 210.57万 USD | 325.09万 USD | 258.14万 USD | 256.95万 USD | 465.85万 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
近期已公布业绩
年度分割调整后的每股现金分配。
US$0.60
2025年(完整年度)-23.1% 自从 2020
2026年(部分年度):US$0.55
US$0.78
2,020
US$1.13
2,021
US$0.68
2,022
US$0.60
2,024
US$0.60
2,025
US$0.55
2,026*
* 在现有股息历史记录中,该日历年仅包含部分期间。
| 行动 | 除息日 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股息 | 2026年7月28日 | US$0.30Semi-Annual | 2026年7月28日 | 2026年8月4日 |
股息 | 2026年2月9日 | US$0.25Semi-Annual | 2026年2月9日 | 2026年2月17日 |
股息 | 2025年7月25日 | US$0.25Semi-Annual | 2025年7月25日 | 2025年8月1日 |
股息 | 2025年2月10日 | US$0.35Semi-Annual | 2025年2月10日 | 2025年2月18日 |
股息 | 2024年7月23日 | US$0.35Semi-Annual | 2024年7月23日 | 2024年7月31日 |
股息 | 2024年2月9日 | US$0.25Semi-Annual | 2024年2月12日 | 2024年2月20日 |
除息 2026年7月28日
US$0.30
Semi-Annual
2026年7月28日登记 · 支付日 2026年8月4日
除息 2026年2月9日
US$0.25
Semi-Annual
2026年2月9日登记 · 支付日 2026年2月17日
除息 2025年7月25日
US$0.25
Semi-Annual
2025年7月25日登记 · 支付日 2025年8月1日
除息 2025年2月10日
US$0.35
Semi-Annual
2025年2月10日登记 · 支付日 2025年2月18日
除息 2024年7月23日
US$0.35
Semi-Annual
2024年7月23日登记 · 支付日 2024年7月31日
除息 2024年2月9日
US$0.25
Semi-Annual
2024年2月12日登记 · 支付日 2024年2月20日
报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI65.35万0.00%2.3万亿 USD0.03%US$381.57-0.10%
Vanguard Extended Market ETFVXF26.07万0.00%954亿 USD0.05%US$233.52-0.63%
U.S. Micro Cap Portfolio ETFDFMC22.91万0.00%75.58亿 USD0.43%US$57.70-0.20%
Dimensional - US Small Cap ETFDFAS13.34万0.00%338.69亿 USD0.31%US$78.17-0.23%
iShares Micro-Cap ETFIWC7.51万0.01%13.17亿 USD0.60%US$181.66-0.73%
EA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSM5万0.04%1.16亿 USD0.73%US$15.8484-0.58%
Dimensional - US Core Equity 2 ETFDFAC3.47万0.00%885.96亿 USD0.21%US$45.31-0.04%
U.S. Core Equity 1 Portfolio ETF Class SharesDCOR1.97万0.00%455.91亿 USD0.17%US$84.43-0.01%
Vanguard Morningstar Total Stock Market ETFVTI
Vanguard Extended Market ETFVXF
U.S. Micro Cap Portfolio ETFDFMC
Dimensional - US Small Cap ETFDFAS
iShares Micro-Cap ETFIWC
EA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSM
Dimensional - US Core Equity 2 ETFDFAC
U.S. Core Equity 1 Portfolio ETF Class SharesDCORAI 生成内容及延迟市场数据仅供信息与教育用途,不构成投资建议。